Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01477424 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study of Warfarin and PA21
A Phase 1 study of Drug Interaction Potentiation, sponsored by Vifor Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT01477424 is a Phase 1 study of Drug Interaction Potentiation that has completed, run by Vifor Pharma. The registered enrollment target is 45 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01477424, a Phase 1 study of Drug Interaction Potentiation, has completed, sponsored by Vifor Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if Warfarin is affected by PA21.
Conditions Studied
Interventions
- DRUG Warfarin
- DRUG PA21
Study Locations (1)
Kansas
- PRA International - Clinical Pharmacology Center - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01477424
The ClinicalTrials.gov registry entry for NCT01477424 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vifor Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug Interaction Potentiation appearing as the primary indexed condition, and to 2 interventions - of which Warfarin is the first listed.
NCT01477424 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT01477424 about?
NCT01477424 is a clinical study titled "A Drug-Drug Interaction Study of Warfarin and PA21". The purpose of this study is to determine if Warfarin is affected by PA21.
What is the current status of trial NCT01477424?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2011-11. Estimated completion is 2012-02.
What conditions does trial NCT01477424 study?
This clinical trial studies the following conditions: Drug Interaction Potentiation.
What interventions are being tested in trial NCT01477424?
The interventions under investigation include: Warfarin (DRUG), PA21 (DRUG).
Who is sponsoring clinical trial NCT01477424?
This trial is sponsored by Vifor Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01477424 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.